SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-007929 to Canopy Growth Corp (CGC)

Canopy Growth Corp
Date: July 25, 2023 · CIK: 0001737927 · Accession: 0000000000-23-007929

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273319

Date
July 25, 2023
Author
David Klein
Form
UPLOAD
Company
Canopy Growth Corp

Letter

United States securities and exchange commission logo July 25, 2023 David Klein Chief Executive Officer Canopy Growth Corporation 1 Hershey Drive Smiths Falls, Ontario, Canada K7A 0A8 Re:Canopy Growth Corporation Registration Statement on Form S-1 Filed July 19, 2023 File No. 333-273319 Dear David Klein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Yariv Katz

Show Raw Text
United States securities and exchange commission logo
July 25, 2023
David Klein
Chief Executive Officer
Canopy Growth Corporation
1 Hershey Drive
Smiths Falls, Ontario, Canada K7A 0A8
Re:Canopy Growth Corporation
Registration Statement on Form S-1
Filed July 19, 2023
File No. 333-273319
Dear David Klein:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Yariv Katz